4D Molecular Therapeutics Inc
NASDAQ:FDMT

Watchlist Manager
4D Molecular Therapeutics Inc Logo
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Watchlist
Price: 10.95 USD 1.01% Market Closed
Market Cap: 625.7m USD

4D Molecular Therapeutics Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

4D Molecular Therapeutics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Operating Income
-$187.8m
CAGR 3-Years
-38%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

4D Molecular Therapeutics Inc
Glance View

Market Cap
625.7m USD
Industry
Biotechnology

4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. The company is headquartered in Emeryville, California and currently employs 124 full-time employees. The company went IPO on 2020-12-11. The firm is focused on creating and developing targeted and evolved adeno-associated viruses (AAV) vectors. The Company’s product candidates are focused various areas, including ophthalmology, cardiology, and pulmonology. The firm's product candidates include 4D-125, 4D-150, 4D-110, 4D-310, and 4D-710. 4D-125 for the treatment of patients with X-Linked Retinitis Pigmentosa (XLRP) with retinitis pigmentosa GTPase regulator (RPGR) gene. 4D-150 is developed for the treatment of wet age-related macular degeneration (wet-AMD). 4D-110 is developed for the treatment of choroideremia. 4D-310 is developed for the systemic treatment of Fabry disease. The firm is developing 4D-710 for the treatment of a broad range of patients with cystic fibrosis independent of their cystic fibrosis transmembrane conductance regulator (CFTR).

FDMT Intrinsic Value
4.07 USD
Overvaluation 63%
Intrinsic Value
Price

See Also

What is 4D Molecular Therapeutics Inc's Operating Income?
Operating Income
-187.8m USD

Based on the financial report for Dec 31, 2024, 4D Molecular Therapeutics Inc's Operating Income amounts to -187.8m USD.

What is 4D Molecular Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-33%

Over the last year, the Operating Income growth was -66%. The average annual Operating Income growth rates for 4D Molecular Therapeutics Inc have been -38% over the past three years , -33% over the past five years .

Back to Top